Results of Aelis Farma Combined General Meeting of May 27, 2025
Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, announces that all the resolutions recommended by the Board of directors were adopted by the Combined General Meeting of shareholders.
Aelis Farma held its combined general meeting of shareholders on May 27, 2025, which was chaired by Mr. Anders Gersel Pedersen, Chairman of the Board of directors.
With a quorum of 74.42 %, the shareholders have adopted all the resolutions recommended by the Board of Directors, in particular the financial statements for the 2024 financial year, the compensation policy applicable to the Chairman, the Chief Executive Officer and the directors, as well as delegations granted to the Board of directors related to financial transactions. The General Assembly also renewed the term of office of all the directors.
Mr. Anders Gersel Pedersen was reappointed as Chairman of the Board of Directors.
Detailed results of the vote on all resolutions, as well as the recording of the general meeting, will be available on the Company's website within the legal time frame.
About AELIS FARMA
Founded in Bordeaux in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the CB1 receptor of the endocannabinoid system (CB1-SSi). CB1-SSi have been developed by Aelis Farma based on the discovery of a natural regulatory mechanism of CB1 hyperactivity made by the team led by Dr Pier Vincenzo Piazza, the Company's CEO, when he was the director of the Neurocentre Magendie of INSERM in Bordeaux. By mimicking this natural mechanism, CB1-SSi appear to selectively inhibit the disease-related activity of the CB1 receptor without disrupting its normal physiological activity. CB1-SSi have consequently the potential to provide new safe treatments for several brain and peripheral organ diseases.
Aelis Farma currently has two first-in-class clinical-stage drug candidates. AEF0117 for the treatment of cannabis use disorders (CUD), that has shown to be able to decrease cannabis use across two studies. AEF0217 for cognitive disorders, which has shown in a Phase 1/2 to be safe and able to improve adaptive behaviour in young adults with Down syndrome (Trisomy 21). The clinical results obtained with these 2 molecules have confirmed the pharmacological activity of CB1-SSi in humans. The Company also has a portfolio of new innovative CB1-SSi for the treatment of other disorders associated with a dysregulation of the activity of the CB1 receptor, including diseases involving peripheral organs, such as obesity and related metabolic conditions. The different drugs developed by the company belong to the same general pharmacological class, the CB1-SSi, but have distinct functional effects allowing to target different types of dysregulations of the CB1 receptor and guaranteeing that the different compounds are not substitutable one with the others.
Aelis Farma draws on the talents of more than 25 highly qualified employees.
For more information, visit www.aelisfarma.com and follow us on LinkedIn and Twitter.
ISIN: FR0014007ZB4Ticker: AELISB Compartment of Euronext Paris
Disclaimer
Forward-looking statements
Some information contained in this press release is forward-looking statements, not historical data. These forward-looking statements are based on current beliefs, expectations, and assumptions, including, but not limited to, assumptions about Aelis Farma's current and future strategy and the environment in which Aelis Farma operates. They involve known and unknown risks, uncertainties, and other factors, which may cause actual results, performance, achievements, or industry results or other events, to differ materially from those described or implied by such forward-looking statements. These risks and uncertainties include those set out and described in detail in Chapter 3 "Risk Factors" of Aelis Farma's Universal Registration Document filed with the Autorité des Marchés Financiers on April 28, 2025, under number D-25.0314.
These forward-looking statements are made only as of the date of this press release and Aelis Farma expressly disclaims any obligation or undertaking to release any updates or corrections to the forward-looking statements included in this press release to reflect any change in expectations or events, conditions, or circumstances on which any such forward-looking statement is based. Forward-looking information and statements are not guarantees of future performance and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond Aelis Farma's control. Actual results could differ materially from those described in, or implied or projected by, forward-looking information and statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250527848780/en/
Contacts
AELIS FARMA Pier Vincenzo PiazzaChief Executive Officercontact@aelisfarma.com
NewCap Dusan Oresansky / Aurélie ManavarereInvestor Relationsaelis@newcap.eu +33 1 44 71 94 92
NewCap Arthur RouilléMedia Relationsaelis@newcap.eu +33 1 44 71 00 15
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Graco Inc. Announces Second Quarter 2025 Earnings Conference Call
MINNEAPOLIS, July 02, 2025--(BUSINESS WIRE)--Graco Inc. (NYSE: GGG) announced today that it will release its Second Quarter 2025 earnings after the New York Stock Exchange closes on Wednesday, July 23, 2025. A full-text copy of the earnings announcement will be available on the company's website at Graco management will hold a conference call, including slides via webcast, with analysts and institutional investors to discuss the results at 11 a.m. EDT / 10 a.m. CDT on Thursday, July 24, 2025. A real-time listen-only webcast of the conference call will be broadcast on the company's website and by going here: Listeners should register on the website at least 15 minutes prior to the live conference call. For those unable to listen to the live event, a replay of the webcast will be available on the company's website at ABOUT GRACO Graco Inc. supplies technology and expertise for the management of fluids in both industrial and commercial applications. It designs, manufactures and markets systems and equipment to move, measure, control, dispense and spray fluid and powder materials. A recognized leader in its specialties, Minneapolis-based Graco serves customers around the world in the manufacturing, processing, construction and maintenance industries. For additional information about Graco Inc., please visit us at View source version on Contacts FOR FURTHER INFORMATION: Investors: David M. Lowe, 612-623-6456Media: Meredith A. Sobieck, 612-623-6427Meredith_A_Sobieck@ Sign in to access your portfolio
Business Wire
19 minutes ago
- Business Wire
CORRECTING and REPLACING SAIF Partners: Now is Your Last Chance to Vote for Board Change at Sinovac
NEW YORK--(BUSINESS WIRE)--Third paragraph, second sentence of release should read: These include the current Board's failure to actively engage with management, its lack of sound financial reasoning for its proposed dividend figures, its apparent unwillingness to hire a new independent auditor after it drove Sinovac's prior public accounting firm to resign in April, and its poor governance practices. The updated release reads: SAIF PARTNERS: NOW IS YOUR LAST CHANCE TO VOTE FOR BOARD CHANGE AT SINOVAC Sinovac's Special Meeting of Shareholders is Just Days Away; Your Vote Matters No Matter How Many Shares You Own SAIF Partners Urges Shareholders to Vote the GOLD Proxy Card ' FOR ' its Director Candidates to End Years of Chaos, Restore Credibility and Unlock Long-Term Value for All Sinovac Shareholders SAIF Partners IV L.P., ('SAIF Partners', 'we' or 'us'), the largest single investor in Sinovac Biotech Ltd. ('Sinovac' or the 'Company') which beneficially owns approximately 15% of the Company's outstanding common shares, today urged shareholders to immediately vote ' FOR ' the election of SAIF Partners' ten highly qualified director candidates to the Company's Board of Directors (the 'Board') using the GOLD proxy card. Sinovac's Special Meeting of Shareholders (the 'Special Meeting') – scheduled for Tuesday, July 8 at 8:00 p.m. Atlantic Standard Time (Wednesday, July 9 at 8:00 a.m. China Standard Time) – is just days away, and time is running out to cast your vote for change. SAIF Partners firmly believes that Sinovac's current Board – the majority of whose members were not duly elected by shareholders or sanctioned by the Privy Council – does not act in the interests of all shareholders, and in fact only began to do so when it was publicly pressured. Further, we believe the current Board lacks integrity, industry experience, management expertise, and respect for the law necessary to fulfill its lofty promises to shareholders. As such, we do not believe the current Board has the capability to resolve the Company's most pressing issues, including concluding its numerous lawsuits and ending the six-year suspension of the trading of Sinovac's common shares in the public markets. Most importantly, however, we are highly skeptical of the current Board's ability to follow through on its plan to issue significant dividends to shareholders for several concerning reasons. These include the current Board's failure to actively engage with management, its lack of sound financial reasoning for its proposed dividend figures, its apparent unwillingness to hire a new independent auditor after it drove Sinovac's prior public accounting firm to resign in April, and its poor governance practices. These issues, among others, lead us to believe that the current Board has put forth its massive dividend distribution plan simply to win shareholders' support and retain their positions, even though it lacks the capabilities to follow through on its stated promise. Ultimately, we believe that meaningful change is urgently needed on Sinovac's Board to restore the Company's credibility with investors and regulators and unlock the tremendous long-term value embedded within Sinovac for all shareholders. If elected, our nominees will work closely with management to deliver shareholders the long-overdue dividends they deserve and establish a long-term business strategy that will maximize the value of the Company for all shareholders. Now is Your Chance to Elect a Board that Will Act in the Best Interest of ALL Sinovac Shareholders Vote the GOLD Proxy Card Today 'FOR' Proposal 1 and Proposal 2 to Remove Sinovac's Current Board and Elect SAIF Partners' Highly Qualified Director Candidates VISIT TO CAST YOUR VOTE USING YOUR UNIQUE CONTROL NUMBER LOCATED ON YOUR GOLD PROXY CARD. IF YOU RECEIVED A GOLD PROXY CARD BY EMAIL, CLICK THE LINK IN YOUR EMAIL TO CAST YOUR VOTE IF YOU DID NOT RECEIVE A GOLD PROXY CARD OR IF YOU HAVE LOST YOUR GOLD PROXY CARD, CHECK YOUR SPAM FOLDER OR CONTACT YOUR BROKER TO ASK FOR YOUR CONTROL NUMBER. IF YOU HAVE ALREADY VOTED USING THE COMPANY'S WHITE PROXY CARD, YOU CAN STILL CHANGE YOUR VOTE BY USING YOUR GOLD PROXY CARD. About SAIF Partners SAIF Partners is a leading Asian private equity firm with cumulative assets under management of over $4 billion. SAIF Partners is an active lead investor working closely with its portfolio companies to develop their business both organically and through acquisitions, seeking synergistic cooperation among them, as well as enhancing shareholder value via promotion of good corporate governance and best management practices. Additional Information and Where to Find It This communication may be deemed to be solicitation material in respect of SAIF Partners' nomination of ten director nominees to Sinovac's Board. In connection with such solicitation, SAIF Partners mailed the definitive proxy statement and proxy card to shareholders of Sinovac with respect to the Special Meeting to be held in connection with the election of directors to Sinovac's Board. The definitive proxy statement mailed by SAIF Partners is also filed as Exhibit 1 to its Schedule 13D/A filed on or about June 16, 2025. SHAREHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC IN CONNECTION WITH SINOVAC'S SPECIAL MEETING, INCLUDING ANY DOCUMENT INCORPORATED BY REFERENCE THEREIN, CAREFULLY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE DIRECTOR NOMINEES AND THE SPECIAL MEETING AND RELATED MATTERS. Sinovac's shareholders may obtain, free of charge, the definitive version of the proxy statement, any amendments or supplements thereto, and any other relevant documents mailed by SAIF Partners in connection with the Special Meeting at
Business Wire
28 minutes ago
- Business Wire
Graco Inc. Announces Second Quarter 2025 Earnings Conference Call
MINNEAPOLIS--(BUSINESS WIRE)--Graco Inc. (NYSE: GGG) announced today that it will release its Second Quarter 2025 earnings after the New York Stock Exchange closes on Wednesday, July 23, 2025. A full-text copy of the earnings announcement will be available on the company's website at Graco management will hold a conference call, including slides via webcast, with analysts and institutional investors to discuss the results at 11 a.m. EDT / 10 a.m. CDT on Thursday, July 24, 2025. A real-time listen-only webcast of the conference call will be broadcast on the company's website and by going here: Listeners should register on the website at least 15 minutes prior to the live conference call. For those unable to listen to the live event, a replay of the webcast will be available on the company's website at ABOUT GRACO Graco Inc. supplies technology and expertise for the management of fluids in both industrial and commercial applications. It designs, manufactures and markets systems and equipment to move, measure, control, dispense and spray fluid and powder materials. A recognized leader in its specialties, Minneapolis-based Graco serves customers around the world in the manufacturing, processing, construction and maintenance industries. For additional information about Graco Inc., please visit us at
